- Home
- FMST vs ICU Comparison
FMST vs ICU Comparison
Compare FMST & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FMST | ICU |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9M | 10.6M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FMST | ICU |
|---|---|---|
| Price | $0.72 | $1.92 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 269.3K | 169.7K |
| Earning Date | 11-24-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,234,000.00 |
| Revenue This Year | N/A | $62.07 |
| Revenue Next Year | N/A | $46.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 814.07 |
| 52 Week Low | $0.42 | $0.22 |
| 52 Week High | $3.49 | $5.38 |
Technical Indicators
Market Signals| Indicator | FMST | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 54.43 | 31.61 |
| Support Level | $0.45 | N/A |
| Resistance Level | $0.90 | $2.85 |
| Average True Range (ATR) | 0.09 | 0.21 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 58.75 | 5.36 |
Price Performance
Historical ComparisonAbout FMST Foremost Lithium Resource & Technology Ltd.
Foremost Clean Energy Ltd is an exploration company focused on the identification and development of high potential mineral opportunities in stable jurisdictions. Its Uranium properties includes Eastern Athabasca, and Blue-Sky. Its Lithium properties includes Zoro Lithium Project, JEAN LAKE LITHIUM GOLD PROJECT, Peg North Project, Grass River Claims Project, and JOL LITHIUM PROJECT.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.